Ensartinib

Ensartinib (X-396) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively.

Product Specifications

CAS Number

[1370651-20-9]

Product Name Alternative

X-396

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Anaplastic lymphoma kinase (ALK) ; c-Met/HGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/X-396.html

Purity

99.93

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=NN=C(N)C(O[C@@H](C2=C(Cl)C=CC(F)=C2Cl)C)=C1)NC3=CC=C(C(N4C[C@@H](C)N[C@@H](C)C4)=O)C=C3

Molecular Formula

C26H27Cl2FN6O3

Molecular Weight

561.44

Precautions

H302, H315, H319, H335

References & Citations

[1]Lovly CM, et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinaseinhibitors. Cancer Res. 2011 Jul 15;71 (14) :4920-31.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Analyst. 2025 Nov 17;150 (23) :5174-5189.|Cancer Discov. 2024 Sep 13:OF1-OF20.|Cancers. 2020 Mar 28;12 (4) :813.|Drug Des Devel Ther. 2020 Nov 30;14:5259-5273.